Immunofluorescence staining against p-ERK1/2 confirmed the inhibition of the MAPK pathway in tumours treated with the MEK inhibitors relative to the controls (p < 0.001) (Fig. 2B). This evidence concerns the gene MAPK3 and neoplasm.